Document Detail

Salmeterol/fluticasone propionate: a review of its use in the treatment of chronic obstructive pulmonary disease.
MedLine Citation:
PMID:  17983257     Owner:  NLM     Status:  MEDLINE    
Salmeterol/fluticasone propionate (Seretide, Advair, Viani) administered using a multidose dry powder inhaler (Diskus, Accuhaler) is approved for use in the treatment of chronic obstructive pulmonary disease (COPD) in numerous countries.Salmeterol/fluticasone propionate administered twice daily via dry powder inhaler is effective and generally well tolerated in patients with COPD. Although not associated with a statistically significant reduction in mortality versus placebo in the TORCH study (p = 0.052), salmeterol/fluticasone propionate reduced the rate of decline in lung function over the 3 years of the trial and was associated with lower exacerbation rates than the component monotherapies or placebo; other trials revealed clinically significant improvements in health status and dyspnoea scores with salmeterol/fluticasone propionate. Results of the INSPIRE trial suggest that salmeterol/fluticasone propionate is associated with a significantly lower mortality rate than tiotropium bromide monotherapy in patients with COPD; the two treatments had similar effects in terms of exacerbation rates and lung function. Thus, salmeterol/fluticasone propionate is an important option in the treatment of patients with COPD who are appropriate candidates for combination therapy with a long-acting bronchodilator and an inhaled corticosteroid.
Gillian M Keating; Paul L McCormack
Related Documents :
7657447 - Steroid-pulse therapy in pemphigus vulgaris long term follow-up.
16602397 - The assessment and management of patients with acute asthma.
1106277 - Azathioprine plus prednisone compared with prednisone alone in the treatment of systemi...
22621937 - A simple audio-visual prompt device can improve cpr performance.
15063237 - Complete laryngotracheal disruption caused by blunt injury.
10674267 - Treatment with lansoprazole also induces hypertrophy of the parietal cells of the stomach.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Drugs     Volume:  67     ISSN:  0012-6667     ISO Abbreviation:  Drugs     Publication Date:  2007  
Date Detail:
Created Date:  2007-11-06     Completed Date:  2008-02-01     Revised Date:  2010-12-02    
Medline Journal Info:
Nlm Unique ID:  7600076     Medline TA:  Drugs     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  2383-405     Citation Subset:  IM    
Wolters Kluwer Health | Adis, Auckland, New Zealand.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Inhalation
Albuterol / analogs & derivatives*,  economics,  pharmacology,  therapeutic use
Androstadienes / economics,  pharmacology,  therapeutic use*
Anti-Inflammatory Agents / economics,  pharmacology,  therapeutic use*
Bronchodilator Agents / economics,  pharmacology,  therapeutic use*
Drug Combinations
Pulmonary Disease, Chronic Obstructive / drug therapy*
Reg. No./Substance:
0/Androstadienes; 0/Anti-Inflammatory Agents; 0/Bronchodilator Agents; 0/Drug Combinations; 0/fluticasone, salmeterol drug combination; 18559-94-9/Albuterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.
Next Document:  Budesonide/formoterol: a review of its use as maintenance and reliever inhalation therapy in asthma.